IN8BIO, INC.
Most recent annual filing: 2026-03-12
Pipeline (6 active programs)
INB-200
INB-400
INB-619
INB-300
- Undisclosed indication
INB-500
- Undisclosed indication
Technology platforms
DeltEx
Gamma-delta T cell platform encompassing allogeneic, autologous, iPSC, and genetically modified cell therapy approaches, plus T cell engagers; disease focus: cancer and autoimmune diseases
INB-600
Proprietary gamma-delta T cell engager (TCE) platform engaging both Vd1+ and Vd2+ TCR populations; disease focus: solid tumors, hematologic malignancies, autoimmune diseases
Biotech Distilled coverage (1)
- 2026-05-14 IN8bio (INAB) - Scientific Deep Dive for Lead and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.